Rajiv Silva - Endo International Insider

ENDP -- USA Stock  

USD 9.30  0.14  1.48%

CEO and President and Director

Mr. Rajiv De Silva is President Chief Executive Officer and a Director of Endo International Public Limited Company. Prior to joining Endo in March 2013 Mr. De Silva joined Endo Health Solutions as Chief Executive Officer and a Director in March 2013 and had served as the President of Valeant Pharmaceuticals International Inc. from October 2010 to January 2013 and served as its Chief Operating Officer Specialty Pharmaceuticals from January 2009 until January 2013. At Valeant he was responsible for all specialty pharmaceutical operations including sales and marketing research and development manufacturing and business development. Prior to joining Valeant Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head Vaccines of the Americas at Novartis. During this time he played a key leadership role at Novartis Vaccines Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel Switzerland. Prior to his time at Novartis Mr. De Silva was a Principal at McKinsey Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. He has broad international experience having managed businesses in the United States Europe Canada Latin America Asia South Africa and AustraliaNew Zealand. Mr. De Silva was a Director of AMAG Pharmaceuticals Inc. and is currently a Member of the Board of Trustees at Kent Place School in Summit NJ.
Age: 48        
353 1 268 2000  http://www.endo.com
De Silva was a Director of AMAG Pharmaceuticals, Inc., a public specialty pharmaceutical company, and is currently a Member of the Board of Trustees at Kent Place School in Summit, NJ. He holds a BS in Engineering, Honors from Princeton University, a MS from Stanford University and a MBA with Distinction from the Wharton School at the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of 3.03 % which means that it generated profit of $3.03 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (143.52) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.27 B in liabilities. Endo International plc has Current Ratio of 1.04 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.

Similar Executives

Found 2 records

CEO Since

Brenton SaundersAllergan plc
2016
Mark TrudeauMallinckrodt Public Limited Com
2013

Entity Summary

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Endo International operates under Drug Manufacturers - Specialty Generic classification in USA and traded on NASDAQ. It employs 30 people.Endo International plc (ENDP) is traded on NASDAQ in USA. It is located in IRELAND and employs 3,039 people. Endo International is listed under Pharmaceutical Products category by Fama And French industry classification.

Endo International plc Leadership Team

Carrie Nichol, President, MBA
William Spengler, Director
Arthur Higgins, Director
Brian Lortie, President
Donald DeGolyer, CEO
William Montague, Director
Michael Hyatt, Director
Douglas Ingram, Director
Antonio Pera, President, MBA
Roger Kimmel, Chairman
Susan Hall, EVP, Ph.D
Sharad Mansukani, Director
Suketu Upadhyay, CFO, CPA
Nancy Hutson, Director
Todd Sisitsky, Director, MBA
Shane Cooke, Director
Craig Paterson, Executive, MBA
Daniel Rudio, President
Camille Farhat, President, MBA
Paul Campanelli, CEO
Jill Smith, Director
Rajiv Silva, CEO
Blaise Coleman, President, MBA
Terrance Coughlin, President
Matthew Maletta, President

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Correlation Now
   

Cryptocurrency Correlation

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges
All  Next Launch Cryptocurrency Correlation

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Endo International and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.